Ross I. Kaye

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Ross

Last Name

Kaye

NPI

1568737831

Faculty ID

18024

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

78694

Is Open Scheduling

Off

Grace R. Kajita

https://assets.montefioreeinstein.org/profiles/images/physphoto/Kajita_Grace_MD_420x504.jpg

First Name

Grace

Last Name

Kajita

NPI

1235176991

Faculty ID

14657

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Kajita completed a bachelor's degree at Barnard College, Columbia University, a medical degree at Albert Einstein College of Medicine, and a primary care medicine residency at NYU School of Medicine. Following residency she became an attending physician for the Department of Veterans' Affairs, New York Harbor Healthcare, where she also served as firm chief for the Department of Medicine and associate program director for the Internal Medicine Residency. In 2005, she was appointed clinical instructor of medicine at NYU Langone Medical Center, where she also served as associate program director for the Internal Medicine Residency. Dr. Kajita's broad range of teaching, administrative, and clinical experience includes the development of a global health elective for internal medicine residents and service as a TB unit supervisor and medical referent for M&eacute;decins Sans Fronti&egrave;res in South Sudan. She is a fellow of the American College of Physicians, MSF-USA Association, and the Association of Program Directors in Internal Medicine. Additionally, Dr. Kajita has received multiple teacher-of-the-year awards at NYU.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

73271

Is Open Scheduling

On

Betsy Herold

https://assets.montefioreeinstein.org/profiles/images/physphoto/Herold_Betsey_MD_420x504.jpg

First Name

Betsy

Last Name

Herold

NPI

1619938206

Faculty ID

10991

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Betsy Herold, M.D.</strong> directs a basic and translational research program, which focuses on virus host interactions. Projects in the lab include studies designed to identify the cellular signaling pathways that herpes simplex viruses (HSV) usurp to promote viral entry and infection. The lab uncovered a previously unappreciated paradigm associated with activation of phospholipid scramblases, which are known to catalyze the movement of phosphatidylserine lipids between the inner and outer leaflet of the plasma membrane. Surprisingly, they found that the exofacial movement of phospholipids is associated with concomitant translocation of intracellular proteins, including the master kinase Akt to the outside, where Akt becomes phosphorylated to activate an &ldquo;outside-inside&rdquo; signaling cascade that promotes viral entry. This pathway is also usurped by SARS-CoV-2 and is important for cellular processes including apoptosis. In collaboration with the Almo lab, they have engineered cell impermeable kinase inhibitors. These compounds block viral entry and prevent induction of apoptosis by select TNF ligands.</p>
<p> Serendipitously, in studying this signaling pathway, the lab identified a novel candidate vaccine for the prevention and treatment of HSV infections.  Most efforts to develop a vaccine have focused on neutralizing antibodies that target HSV glycoprotein D (gD), but all of these have failed in clinical trials. Instead, the lab (in collaboration with the Jacobs lab), engineered a virus completely deleted in gD. Glycoprotein D is required for viral entry and cell-to-cell spread, thus the deletion virus (DgD-2) is restricted a single cycle and will not spread. This candidate vaccine elicits T cell responses and high titer, polyfunctional antibodies that protect through antibody-dependent cell mediated cytotoxicity (ADCC). The vaccine prevents the establishment of latency in mice and is significantly more protective in multiple small animal models than prior vaccines that have failed in clinical trials. The lab has subsequently isolated monoclonal antibodies (mAbs) that have this protective ADCC activity and both the vaccine and the mAbs are being advanced for preclinical development.  Studies to understand why this vaccine elicits ADCC-mediating antibodies whereas gD vaccines and primary HSV infection only elicit neutralizing antibodies led to the identification of a key role for TNFRSF14 (aka HVEM) in generating and mediating ADCC responses. HVEM is an immune cell surface protein that functions in signal transduction pathways that regulate inflammatory or inhibitory immune responses but its role in shaping the B cell repertoire and in providing a second signal for ADCC had not been previously described and has implications for vaccine development and oncolytic therapies. </p>
<p> The third major area of basic research involves defining the molecular mechanisms underlying the HIV-HSV syndemic. Epidemiological studies have consistently demonstrated that being HSV seropositive is associated with an increased risk for HIV acquisition, replication, higher plasma viral loads and more frequent episodes of HIV reactivation.  Using primary cells from patients and HIV latently infected cell lines, the lab has identified several mechanisms by which HSV promotes HIV latency reversal and replication including upregulation of the noncoding RNA, <em>Malat1</em>, and downregulation of IL-32. Defining these pathways may lead to identification of new strategies to &ldquo;shock and kill&rdquo; or &ldquo;block and lock&rdquo; HIV.</p>
<p> Clinical studies include prevention of infectious disease complications in transplantation. Members of the research group are involved in studies to optimize pre-emptive prophylaxis for CMV and EBV, vaccine responses in transplantation recipients, and others</p><p>Studies with vaginal microbicides have resulted in the expnasion of studies to focus on soluble mucosal immunity in the genital tract. We found that .female genital tract secretions collected from healthy women provide variable, but significant protection against both HSV and HIV. Mechanistic studies suggest that this endogenous activity is mediated by defensins and other antimicrobial peptides. This endogenous activity may serve as a biomarker of a "healthy mucosal immune environment" and thus provide a surrogate marker to evaluate the safety of vaginal microbicides. In addition, identification of the mediators that contribute to this endogenous activity could lead to development of new strategies to boost this host defense and help protect against infection. These studies are being conducted in collaboration with the proteomics core facility at AECOM. Additionally, we are testing the hypothesis that HSV triggers changes in the mucosal environment, which allow it to escape cervical secretion defenses, enhance its own infectivity and facilitate HIV co-infection. Our preliminary observations support the paradigm that HSV disrupts the epithelial barrier by targeting tight junction and adherens junction proteins, and interferes with host defenses by triggering an inflammatory response and a loss in protective proteins such as SLPI. These changes could facilitate both its own infectivity and enhance HIV co-infection.<br /><br /></p>
<p>Results obtained from this bench research are critical to the laboratory's translational studies. The focus of the Translational Microbicide Research Program is to identify optimal combinations of topical microbicides that are safe and target different steps in HIV life cycle, thus reducing the risks of drug resistance and providing greater protection than could be achieved with a single agent, and also target HSV infection. Candidate combinations are evaluated using a multi-tiered approach for anti-viral activity and safety using human cervical cultures, as well as primary T cells and macrophages, in the presence of cervicovaginal secretions and seminal plasma. Leading combinations are then evaluated in human explant cultures (cervical, vaginal) and in murine genital models and a new cotton rat model for anti-viral activity and for the impact on mucosal immunity. If results of these pre-clinical studies suggest that candidate microbicides are safe and effective, the drugs are advanced for regulatory testing, and undergo evaluation in Phase I clinical studies.<br /><br /></p>
<p>Clinical research interests also include prevention of infectious disease complications in transplantation. Members of the research group are involved in studies to optimize pre-emptive prophylaxis for CMV and EBV, vaccine responses in transplantation recipients, and other related infectious complications.<br /><br /></p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<div>Dr. Herold directs a translational research program focused on the interactions between viruses and their host and using that knowledge to develop novel treatment and prevention strategies. Through her basic science studies, Dr. Herold has developed a unique candidate vaccine to prevent herpes simplex virus (HSV) infections, which is being advanced for phase I clinical trials. Studies of this vaccine uncovered a previously unappreciated immune evasion strategy; this knowledge may accelerate the development of drugs to bolster vaccine and monoclonal antibody efficacy against a range of pathogens.&nbsp;</div>
<div><span style="white-space: pre;"> </span>&nbsp;</div>
<div>Her studies on HIV focus on the development of safe and effective pre-exposure prophylactic strategies and on investigating how HSV interacts with HIV to reactivate HIV. Dr. Herold's team also has discovered a previously unrecognized phenomenon in cell biology in which HSV and other viruses activate a mechanism that helps them gain entry and infect healthy cells. This provides a novel target for the development of new antiviral drugs.&nbsp;<br /><br /></div>
<div>Most recently, her lab has studied why children respond differently and are relatively protected from severe COVID-19. Defining the differences in the immune response in children compared to adults will provide insights into protective immunity against this virus and future pandemic viruses.&nbsp;<br /><br /></div>
<div>Her clinical research focuses on infections in pediatric transplant recipients. Dr. Herold helped established and is co-chair of the Pediatric Infectious Diseases Society Transplant Research Network (PIDTRAN), which supports and promotes projects to prevent and treat infectious diseases among child transplant recipients. Dr. Herold has served on the Office of AIDS Research Advisory Council and on the Pediatric Infectious Diseases Society Council. She has been continuously funded by the NIH since 1989. Dr. Herold has over 180 publications in peer-reviewed journals and has presented her work internationally.</div>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Pediatric Infectious Diseases.

Research Focus

Prevention and treatment of infections in solid and stem cell transplant patients and other immunocompromised patients.

Elsevier Profile

EMR ID

4968

Biography

<p>Betsy Herold, MD, is Chief of the Division of Pediatric Infectious Diseases and Vice Chair for Research at Children's Hospital at Montefiore. Dr. Herold is also a Professor of Pediatrics, Microbiology &amp; Immunology, and Obstetrics &amp; Gynecology and Women's Health at our Albert Einstein College of Medicine. She specializes in pediatric infectious diseases. </p><p>Dr. Herold received her Bachelor of Arts in Biology in 1978 from Brown University and went on to receive her Doctor of Medicine from the University of Pennsylvania Medical School in 1982. Dr. Herold completed an internship and residency in pediatrics at Children's Memorial Hospital, where she became a Chief Resident in 1985. She then began a fellowship in research at Hagedorn Research Laboratory in Gentofte, Denmark. In 1987, Dr. Herold began a fellowship in pediatric infectious diseases at Children's Memorial Hospital, followed by a Research Associate/Postdoctoral Virology Fellowship in the Department of Microbiology and Immunology at Northwestern University in Chicago. </p><p>Dr. Herold's clinical research focuses on the prevention and treatment of infections in solid and stem cell transplant patients and other immunocompromised patients. Dr. Herold has also been involved in research in Kawasaki disease and the emergence of methicillin-resistant staphylococcus aureus (MRSA) in the community. Dr. Herold directs a basic and translational research program on the prevention of herpes simplex virus (HSV) and HIV infections through the development of vaccines and novel antivirals. The current major focus of her lab is on a novel, paradigm-shifting, single-cycle vaccine to prevent HSV-1 and HSV-2. She has been continuously funded by the NIH since 1989. Dr. Herold has over 150 peer reviewed publications in peer-reviewed journals and has presented her work internationally. </p><p>In 2012, Dr. Herold received the Clinical Science Faculty Mentor Award from the Albert Einstein College of Medicine. She has also been awarded the Henry and Jacob Lowenberg Prize in Pediatrics and the Pediatric Infectious Disease Young Investigator Award. Dr. Herold is board certified by the American Board of Pediatrics in Pediatrics and in Pediatric Infectious Diseases. </p>

Is Open Scheduling

Off

Valentyna Goloborodko

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/061db580-470d-11ec-9350-298b34a4a389.jpg

First Name

Valentyna

Last Name

Goloborodko

NPI

1194010728

Faculty ID

13925

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5492

Is Open Scheduling

Off

Lauren Gluck

https://assets.montefioreeinstein.org/profiles/images/physphoto/Gluck_Lauren_MD_420x504.jpg

First Name

Lauren

Last Name

Gluck

NPI

1033524780

Faculty ID

16274

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>After receiving her medical degree from the University at Buffalo School of Medicine, Dr. Gluck completed her medicine internship and neurology residency at Montefiore Medical Center and then her neuroimmunology fellowship at Yale University. She specializes in the diagnosis and treatment of adult and adolescent multiple sclerosis, neuromyelitis optica, neurosarcoidosis, autoimmune encephalitis, and other inflammatory diseases that affect the central nervous system.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Diagnosis and treatment of adult and adolescent multiple sclerosis, neuromyelitis optica, neurosarcoidosis, autoimmune encephalitis, and other inflammatory diseases that affect the central nervous system

Research Focus

Clinical outcomes in multiple sclerosis

Elsevier Profile

EMR ID

29225

Biography

<p>Lauren Gluck, MD, is the Director of the Montefiore Multiple Sclerosis Center and Assistant Professor at our Albert Einstein College of Medicine. Her clinical focus is on neuroimmunological diseases that affect the brain and spinal cord, including adult and adolescent multiple sclerosis, neuromyelitis optica, neurosarcoidosis and autoimmune encephalitis.</p><p>In 2010, Dr. Gluck received her Bachelor of Science in biology and community health at Tufts University. She went on to University at Buffalo School of Medicine and Biomedical Sciences, earning her Doctor of Medicine in 2014. She completed her medicine internship and neurology residency at Montefiore Medical Center in 2018, followed by a clinical fellowship in neuroimmunology at Yale New Haven Hospital in 2019.</p><p>Dr. Gluck&rsquo;s research focus is on the clinical outcomes of multiple sclerosis as well as medical education. She has presented her work at several national and international meetings and has published original communications in many reviewed journals.</p><p>Dr. Gluck has received many recognitions, including the American Academy of Neurology Medical Student Prize for Excellence in Neurology in 2014, and becoming a Consortium of MS Centers Mentorship Forum Scholar in 2018. She is board certified in neurology and is a member of several professional organizations, including the American Medical Association, the American Academy of Neurology and the Federation of Clinical Immunology Societies.</p>

Is Open Scheduling

Off

Sameen Farooq

https://assets.montefioreeinstein.org/profiles/images/sameen-farooq.jpg

First Name

Sameen

Last Name

Farooq

NPI

1912391822

Faculty ID

16635

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p>Dr. Farooq is board certified in Internal Medicine, Addiction Medicine, Palliative and Hospice Medicine and Obesity Medicine. He works as a direct care Internal Medicine hospitalist at Moses campus.</p>

EMR ID

76398

Is Open Scheduling

Off

Susan E. Duberstein Coad

https://assets.montefioreeinstein.org/profiles/images/physphoto/Duberstein_Susan_MD_420x504.jpg

First Name

Susan

Last Name

Duberstein Coad

NPI

1447548599

Faculty ID

14253

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

5383

Biography

<p>Susan Duberstein, MD, is Associate Professor, Child Neurology and Pediatrics at Montefiore Einstein. Dr. Duberstein is an epileptologist with a special interest in complex care. She is the collaborating neurologist for the Linking Individual Needs of Children with Services (LINCS) clinic, which provides a &ldquo;medical home&rdquo; and family-centered care for children with chronic illnesses, multiple conditions and medical technologies. She is also the Associate Director of the Neurocutaneous Clinic, serving children with neurofibromatosis, Sturge-Weber, tuberous sclerosis complex and other neurocutaneous conditions.</p><p>After earning her Doctor of Medicine at the State University of New York Downstate Medical Center in 2008, Dr. Duberstein completed her internship and residency in pediatrics at the same institution in 2010. She then came to Montefiore Einstein to continue her medical training, completing her residency in child neurology in 2013 and a fellowship in clinical neurophysiology and electroencephalography (EEG) in 2014.</p><p>Dr. Duberstein's research focuses include retrospective studies on neurofibromatosis and tuberous sclerosis complex. She is also one of the leaders of a research project investigating the clinical outcomes of autoimmune encephalopathies. Her work has been published in numerous peer-reviewed journals, book chapters and abstracts.</p><p>Dr. Duberstein is board certified by the American Board of Psychiatry and Neurology in Neurology with a special qualification in Child Neurology and holds a subspecialty certificate in Epilepsy. She is a member of the American Academy of Neurology, the Child Neurology Society and the American Epilepsy Society. Dr. Duberstein was elected a Fellow of the American Epilepsy Society in 2022.</p>

Is Open Scheduling

Off

Daniel J. Correa

https://assets.montefioreeinstein.org/profiles/images/daniel-correa.jpg

First Name

Daniel

Last Name

Correa

NPI

1366604068

Faculty ID

15444

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>&nbsp;</p>
<p>Daniel J. Correa, MD, MSc, is a member to the research team for the Public Engagement Core of The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx), working with a consortium of researchers, clinicians, patient organization representatives, patients, and caretakers in TBI and Epilepsy to improve public involvement for future treatment trials. His clinical work at Montefiore Medical Center includes inpatient general neurology and epilepsy services, inpatient epilepsy monitoring, long term EEG monitoring of acutely ill patients. Additionally, he supports the NYC Health Hospitals (Jacobi and North Central Bronx) as an epilepsy attending in their clinical neurophysiology lab. Administratively, he serves as the Deputy Chief of Neurology at the Montefiore Medical Center. After Neurology residency at the Walter Reed National Military Medical Center, he served in the US Army Medical Corps advancing to the rank of Major and received numerous decorations and awards throughout 8 years of active duty service. His military assignments included the Deputy Chief and later Chief of the Neuroscience &amp; Rehabilitation Center, Dwight Eisenhower Army Medical Center (EAMC). At the EAMC he also participated in the clinical education of medical students, residents, and post-doctoral trainees; Neuroscience representative on the Institutional Review Board, and participated in growing a program of neuroscience research. His academic and research interests focus on the areas of traumatic brain injury and epileptogenesis in post-traumatic epilepsy. Under the mentorship of Drs. Solomon L. Mosh&eacute; and Nathalie Jett&eacute;, in 2019 he completed a Master of Science in Clinical Research Methods through the Albert Einstein College of Medicine Clinical Research Training Program. His present work focuses on developing solutions for barriers in the recruitment and implementation of critical care and epilepsy clinical research.<br /><br />In his community outreach and volunteer efforts, Dr. Correa joined a Neurology mission to the Ecuadorian Amazon Rainforest, and previously volunteered as Medical Translator for a Pediatric Cardiology mission to Guayaquil, Ecuador. In New York City he serves on the board of the New York Aikido Society (Bond Street Dojo), an organization dedicated to teaching principles of non-violence, conflict resolution and personal development. He hopes to continue to support local and international community efforts to bridge the community health gaps for underserved communities.</p>
<p>&nbsp;</p>
<p><strong>Languages</strong></p>
<p>English, Spanish</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Lab Website Link

Selected Publications

<p>Vazquez J, Islam T, Beller J, Fiori K, Correa R, <strong>Correa DJ</strong>. Expanding Paid Sick Leave as a Public Health Tool in the Covid-19 Pandemic. J Occup Environ Med. 2020 Oct;62(10):e598-e599. doi: 10.1097/JOM.0000000000001998. PubMed PMID: 33009344.</p>
<p>Vazquez J, Islam T, Gursky J, Beller J, <strong>Correa DJ</strong>. Access to Care Matters: Remote Health Care Needs During COVID-19. Telemed J E Health. 2020 Sep 30;. doi: 10.1089/tmj.2020.0371. [Epub ahead of print] PubMed PMID: 33017270.<strong>Correa DJ</strong>, Labovitz DL, Milstein MJ, Monderer R, Haut SR. Folding a neuroscience center into streamlined COVID-19 response teams: Lessons in origami. Neurology. 2020 Sep 29;95(13):583-592. doi: 10.1212/WNL.0000000000010542. Epub 2020 Jul 30. PubMed PMID: 32732292.</p>
<p>Galanopoulou AS, Ferastraoaru V, <strong>Correa DJ</strong>, Cherian K, Duberstein S, Gursky J, Hanumanthu R, Hung C, Molinero I, Khodakivska O, Legatt AD, Patel P, Rosengard J, Rubens E, Sugrue W, Yozawitz E, Mehler MF, Ballaban-Gil K, Haut SR, Mosh&eacute; SL, Boro A. EEG findings in acutely ill patients investigated for SARS-CoV-2/COVID-19: A small case series preliminary report. Epilepsia Open. 2020 Jun;5(2):314-324. doi: 10.1002/epi4.12399. eCollection 2020 Jun. PubMed PMID: 32537529; PubMed Central PMCID: PMC7289172.</p>
<p><strong>Correa DJ</strong>, Milano L, Kwon CS, Jett&eacute; N, Dlugos D, Harte-Hargrove L, Pugh MJ, Smith JK, Mosh&eacute; SL. Quantitative readability analysis of websites providing information on traumatic brain injury and epilepsy: A need for clear communication. Epilepsia. 2020 Mar;61(3):528-538. doi: 10.1111/epi.16446. Epub 2020 Feb 24. PubMed PMID: 32096225; PubMed Central PMCID: PMC7309702.</p>
<p>Hamilton RH, McClean JC 2nd, Greicius MD, Gamaldo CE, Burrus TM, Charleston L 4th, <strong>Correa DJ</strong>, Ebong IM, Hamilton R, Lewis S, Thomas RP, Vargas A, Flippen CC 2nd. Rooting out racial stereotypes in Neurology&reg;: A commentary on "Lucky and the root doctor". Neurology. 2019 May 28;92(22):1029-1032. doi: 10.1212/WNL.0000000000007578. Epub 2019 May 3. PubMed PMID: 31053666.</p>
<p><strong>Correa DJ</strong>, Kwon CS, Connors S, Fureman B, Whittemore V, Jett&eacute; N, Mathern GW, Mosh&eacute; SL. Applying participatory action research in traumatic brain injury studies to prevent post-traumatic epilepsy. Neurobiol Dis. 2019 Mar;123:137-144. doi: 10.1016/j.nbd.2018.07.007. Epub 2018 Jul 18. Review. PubMed PMID: 30031158; PubMed Central PMCID: PMC6338533.</p>
<p><strong>Correa, D.J.</strong>; Osiowy, K; Jett&eacute;, N; Mosh&eacute;, S.L. TBI and Epilepsy: Objectives and Design of a Participatory Action Research Study to Develop Effective Anti-epileptogenic Treatments. All Russian Academy of Sciences, All-Russian Society of Neurologists. International Congress (in honor of) World Stroke Day. Materials of congress. Editors: E.I. Gusev, A.B. Gecht, M.Yu. Martynova, M.: 000 Buki Vedi, Moscow, 2017, 221-231 p. 760 c.</p>
<p>Hardy&nbsp;JJ, Mooney&nbsp;SR, Pearson&nbsp;AN, McGuire&nbsp;D, <strong>Correa&nbsp;DJ</strong>, et al. (2017)&nbsp;Assessing the accuracy of blood RNA profiles to identify patients with post-concussion syndrome: A pilot study in a military patient population. PLOS ONE 12(9): e0183113.&nbsp;<a href="https://doi.org/10.1371/journal.pone.0183113">https://doi.org/10.1371/j…;. PMID: 28863142</p>
<p><strong>Correa, D.,</strong> &amp; Landau, M.E. (2013). Ranolazine-induced myopathy in a patient on chronic statin therapy &ndash; Case Report. Journal of Clinical Neuromuscular Disease, 14(3), 114-6. PMID: 23492463</p>
<p>Williams, S, <strong>Correa, D.,</strong> Lesage, S, &amp; Lettieri, C. (2013). Electroencephalographic hypersynchrony in a child with night terrors &ndash; Case Report. Sleep and Breathing, 17(2), 465-7. PMID: 22773270</p>
<p>Xie, D., Zhong, Q., Ding, K., Cheng, H., Williams, S., <strong>Correa, D.,</strong> Bollag, W., Bollag, R., Insogna, K., Troiano, N., Coady, C., Hamrick, M., &amp; Isales, C.M. (2007). Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone, 40, 1352-1360. PMID: 17321229</p>
<p>Xie, D., Cheng, H., Hamrick, M., Zhong, Q., Ding, K.H., <strong>Correa, D.</strong>, Williams, S., Mulloy, A., B 17(2):465-7 ag, W., Bollag, R.J., Runner, R.R., McPherson, J.C., Insogna, K., &amp; Isales CM.(2005). Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone, 37, 759-769. PMID: 16219496</p>
<h3>In the News</h3>
<p>Dr. Correa interviews the American Academy of Neurology Leadership Program TLP '20 graduate Dr. Nada El Husseini about Duke Neurology "Transforming tele-stroke care in the face of crisis" during Covid19. https://www.aan.com/conferences-community/leadership-programs/aan-leade…;
<p>Dr. Correa describing experiences at Montefiore during the Covid19 spring 2020 surge. Invited Commentary: Answering the call to help COVID-19 patients on internal medicine wards. May 20, 2020. https://blogs.neurology.org/covid-19-coronavirus/invited-commentary-ans… 20, 2020&nbsp;</p>
<p>Dr. Correa and colleagues&nbsp;advocating for changes to the treatment of&nbsp;<a href="https://www.facebook.com/hashtag/immigrants?__eep__=6&amp;source=feed_t…; data-ft="{&quot;type&quot;:104,&quot;tn&quot;:&quot;*N&quot;}"><span aria-label="hashtag">#</span>immigrants</a>&nbsp;as public health measure to mitigate this&nbsp;<a href="https://www.facebook.com/hashtag/pandemic?__eep__=6&amp;source=feed_tex…; data-ft="{&quot;type&quot;:104,&quot;tn&quot;:&quot;*N&quot;}"><span aria-label="hashtag">#</span>pandemic</a>&nbsp;crisis. You health is dependent on the community health.&nbsp;<a href="https://apnews.com/4def0ef4896285765a6fba28c47597d3">https://apnews.com…;
<p>Javier E. Gomez interviews Dr. Daniel Jos&eacute; Correa on <a href="https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.yo… TV "Diagolo Abierto"</strong></a> about &ldquo;La Epilepsia: Sintomas y Tratamientos&rdquo;. <em>A discussion about the basics of Epilepsy, symptoms, and treatments</em>.&nbsp;</p>
<p>The Brain Injury Association of America and Dr. Correa raise awareness among Brain Injury patients about ongoing research in TBI. &ldquo;BRIDGING THE BRAIN INJURY DIVIDE: Working Together to Understand and Prevent Epilepsy After Traumatic Brain Injury. Brain Injury Association Of America&rdquo;. BIAA Newsletter &ldquo;THE Challenge!&rdquo;. Volume 11, Issue 3. Pages 4-6. <a href="http://www.biausa.org/brain-injury-publications.htm">http://www.biausa…;

EMR ID

87363

Biography

<p>Daniel Jos&eacute; Correa, MD is Deputy Chief of Neurology at Montefiore and Assistant Professor of Neurology at our Albert Einstein College of Medicine. His clinical focuses include inpatient epilepsy monitoring, long-term EEG monitoring of acutely ill patients, and general neurology inpatient services.</p><p>Dr. Correa received his Bachelor of Science in biology at the University of Mary Washington in 2004. He continued his studies at Howard University College of Medicine, where he received his Doctor of Medicine in 2008. Dr. Correa completed his residency in neurology at Walter Reed National Military Medical Center in 2012. He fulfilled his army duty at Dwight D. Eisenhower Army Medical Center, departing in 2016 as Chief of the Neuroscience and Rehabilitation Center.</p><p>Dr. Correa came to Montefiore to complete a fellowship in neurophysiology and epilepsy in 2017. During this time, Dr. Correa worked in parallel to receive his Master of Science in clinical research methods at Albert Einstein College of Medicine, which he completed in 2019.</p><p>Dr. Correa&rsquo;s research explores areas of traumatic brain injury and epileptogenesis in post-traumatic epilepsy. His work focuses on developing solutions for implementation barriers in critical care and epilepsy clinical research.</p><p>He is a member of the American Academy of Neurology, NHMA, and the American Epilepsy Society. </p>

Is Open Scheduling

Off

Roy S. Chuck

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/99124b00-b3a6-11ee-8ab8-012a307002d3.jpg

First Name

Roy

Last Name

Chuck

NPI

1447202338

Faculty ID

11721

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="bodycopy">Dr. Roy S. Chuck is an ophthalmologist, visual scientist and geneticist known for his stem cell and dry eye research, and work in corneal restoration. He chairs Einstein&rsquo;s department of ophthalmology and visual sciences, one of only a handful of Asian-Americans to hold such a post in the U.S.</p>
<p class="bodycopy">&nbsp;</p>
<p class="bodycopy">He also chairs the ophthalmology department at Montefiore Medical Center, overseeing tertiary care to adult and pediatric patients with diseases of the eye, with subspecialty expertise that includes neuro-ophthalmology, plastic surgery, and retina, cornea and glaucoma services. The department maintains a program of ongoing community outreach aimed at early detection and treatment of eye diseases.</p>
<p class="bodycopy">&nbsp;</p>
<p class="bodycopy">Dr. Chuck is a cornea specialist with expertise in laser techniques for refractive eye conditions. He has deep research experience and holds multiple patents. His two main areas of research are corneal stem cell surgery and dry eye, the most common global eye disease. Recently, Dr. Chuck's team developed a unique mouse model of dry eye that allows animal testing of therapies. The model employs the use of <em>botulinum</em> toxin, commonly known as "botox," to block neurotransmitters in the tear-producing lacrimal gland. The resulting dry eye closely mimics that found in humans.</p>
<p class="bodycopy">&nbsp;</p>
<p class="bodycopy">Dr. Chuck is a long-time stem cell investigator in connection with corneal transplantation and sight restoration. His work includes cutting-edge corneal stem cell surgery, which has a success rate of nearly 50-percent&mdash;one of the highest for stem cell surgery.&nbsp; The operation is performed if the stem cell pool on the eye is wiped out through injury or a genetic condition. Without these regenerating cells, eye injuries, however small, result in opaque scars that reduce or even eliminate vision. Corneal stem cell surgery requires removing the scar tissue and transplanting donated corneal stem cells onto the eye. If successful, the introduced stem cells heal the wound and vision is restored.</p>
<p class="bodycopy">&nbsp;</p>
<p class="bodycopy">At Einstein, Dr. Chuck is developing research centers focusing on ophthalmologic disorders including cataracts, ocular surface disease/dry eye, glaucoma, macular degeneration, and eye conditions associated with diabetes.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<div>Dr. Chuck is a prominent stem cell and dry eye researcher. He is a cornea specialist with expertise in the field of laser techniques, including LASIK surgery, corneal replacement, stem cell surgery, and refractive eye problems.&nbsp;</div>
<div><br />A basic scientist as well as a clinical researcher, Dr. Chuck has helped develop a unique model of dry eye using Botox that allows for testing of preclinical therapies. He has served as principal investigator on five FDA studies of vision correction and written more than 175 peer-reviewed papers and more than 100 book chapters and abstracts. Dr. Chuck has been featured several times on ABC News and ABC&rsquo;s &ldquo;Good Morning America&rdquo; on various eye diseases and conditions. He serves on the editorial boards of several publications, including the <em>Journal of Refractive Surgery</em> and <em>Lasers in Surgery and Medicine</em>.&nbsp;</div>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Refractive surgery and corneal disorders including dry eye

Research Focus

Corneal reconstruction and stem cell surgery, dry eye, refractive surgery

Elsevier Profile

EMR ID

5233

Biography

<p>Roy S. Chuck, MD, PhD, is Chairman and Professor, Ophthalmology &amp; Visual Sciences at Montefiore Einstein. Dr. Chuck&rsquo;s clinical focus is in cornea and external diseases as well as refractive surgery.</p><p>After earning his Bachelor of Science in engineering at University of California, Berkeley, in 1986, Dr. Chuck attended Columbia University, earning his Doctor of Medicine and Doctor of Philosophy in 1993. He started his postdoctoral training at St. Mary&rsquo;s Health Center, completing a yearlong internship in internal medicine in 1994. From then until 1998, he pursued a residency in ophthalmology at Washington University and Barnes Hospital, acting as chief resident in his final year. In 1999, he completed a yearlong fellowship in cornea and refractive surgery at Doheny Eye Institute, University of Southern California.</p><p>Dr. Chuck&rsquo;s research has been published in numerous peer-reviewed journals as well as shared through many abstracts, book chapters and podium and poster presentations. He has been an editor and served on the editorial boards of many publications including the <em>Lasers in Surgery and Medicine, Journal of Refractive Surgery, Current Opinion in Ophthalmology and BMC Ophthalmology</em>. He currently serves as the Editor-in-Chief of the major journal <em>ARVO Translational Vision Science and Technology</em> and is a member of the NIH National Eye Institute Council of Editors.</p><p>Dr. Chuck is board certified and is a member of many local, national and international professional societies including the International Society for Refractive Surgery, the American Society for Laser Medicine and Surgery, and the Manhattan Ophthalmological Society. He currently serves as Secretary for Quality of Care for the American Academy of Ophthalmology.</p>

Is Open Scheduling

Off

Geoffrey H. Basson

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/cbe4c680-8828-11ec-8359-516abccc70f6.jpg

First Name

Geoffrey

Last Name

Basson

NPI

1427038603

Faculty ID

11179

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Neuro-Ophthalmology.&#160;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Neuro-Ophthalmology: Diagnosis and management of visual disorders due to neurologic or neuromuscular, rather than strictly ocular, causes.</p>

Research Focus

Clinical treatment paradigms for ophthalmic manifestations of CNS pathology.

EMR ID

3188

Biography

<p>Geoffrey H. Basson, MD, is an Attending Physician in neuro-ophthalmology and Assistant Professor, Ophthalmology and Visual Sciences and Neurology at Montefiore-Einstein. Dr. Basson&rsquo;s clinical specialty is neuro-ophthalmology&mdash;the diagnosis and management of visual disorders due to neurological or neuromuscular causes.</p><p>After earning his Bachelor of Arts from Columbia College in 1960, Dr. Basson attended the University of Pittsburgh School of Medicine, earning his Doctor of Medicine in 1965. His postdoctoral training began at Duke University Hospital, with an internship in internal medicine and a first-year residency in neurology. His medical training was interrupted by military service, following which he came to Montefiore Medical Center, completing a residency in neurology in 1971 and a residency in ophthalmology in 1978.&nbsp; Dr. Basson is board-certified in both specialties and is a senior fellow of the North American Neuro-Ophthalmology Society.</p><p>Dr. Basson&rsquo;s practice focuses on diagnosis and treatment of those central nervous system and neuromuscular disorders which produce disturbances of vision.</p>

Is Open Scheduling

Off